6 completed, 2 terminated. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 4 | Completed 2, Terminated 2 |
Follow AZD5718: new trials by email Literature Review of AZD5718 trials Research Report on AZD5718
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma Atuliflapon, Placebo - Asthma | Phase 2 | Completed | AstraZeneca | 670 | 2022-01-27 | 2026-01-14 |
| PASSIvation of Vulnerable Plaque With AZD5718 in AcuTe Coronary syndromE AZD5718, Placebo - Acute Coronary Syndrome | Phase 2 | Terminated | National University Heart Centre, Singapore | 243 | 2021-07-12 | 2025-04-27 |
| Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers AZD5718 - Chronic Kidney Disease | Phase 1 | Completed | AstraZeneca | 16 | 2021-02-01 | 2021-12-06 |
| A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease AZD5718, Dapagliflozin 10 mg, Placebo - Chronic Kidney Disease | Phase 2 | Terminated | AstraZeneca | 613 | 2020-10-01 | 2024-12-20 |
| A Study to Assess the Effect of Multiple Doses of AZD5718 on Pharmacokinetics of Oral Midazolam in Healthy Subjects Midazolam, AZD5718 - Cardiovascular Disease | Phase 1 | Completed | AstraZeneca | 14 | 2020-07-30 | 2020-11-03 |
| A Study to Assess the Amount of Drug Levels in Blood and Safety of AZD5718 Formulations in Healthy Volunteers AZD5718 tablet, Formulation A, AZD5718 tablet, Formulation B, AZD5718 tablet, Formulation C - Coronary Artery Disease (CAD) | Phase 1 | Completed | AstraZeneca | 12 | 2020-01-14 | 2020-03-25 |
| A Study to Assess the Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers Form 1 of AZD5718 tablets, Form 2 of AZD5718 tablets, Form 3 of AZD5718 tablets - Coronary Artery Disease | Phase 1 | Completed | AstraZeneca | 14 | 2018-02-05 | 2018-04-23 |
| AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD). AZD5718, Placebo - Coronary Artery Disease | Phase 2 | Completed | AstraZeneca | 129 | 2017-10-30 | 2021-06-30 |
Coronary Artery Disease (3) · Renal Insufficiency, Chronic (2) · Acute Coronary Syndrome (1) · Asthma (1) · Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Diabetic Nephropathies (1) · Proteinuria (1)
AstraZeneca (7) · National University Heart Centre, Singapore (1)
United Kingdom (5) · Argentina (2) · Germany (2) · Hungary (2) · Japan (2) · Poland (2) · Ukraine (2) · United States (2) · Australia (1) · Brazil (1) · Bulgaria (1) · Chile (1) · Croatia (1) · Denmark (1) · Finland (1)
A. Mark Richards (1) · Derek Hausenloy (1) · Dr Pablo Forte Soto (1) · Dr. Pablo Forte Soto, MD, MSc, PhD (1) · Hiddo J. L. Heerspink (1) · Mark Chan (1) · Pablo Forte Soto, Dr (1) · Pablo Forte Soto, MD (1)
2023 (1)